Literature DB >> 23877223

Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms.

Nathalia Daflon-Yunes1, Flavio Eduardo Pinto-Silva, Raphael Silveira Vidal, Bruna Fortunato Novis, Tandressa Berguetti, Raphael Rodrigues Soares Lopes, Carla Polycarpo, Vivian M Rumjanek.   

Abstract

The multidrug-resistant (MDR) phenotype is multifactorial, and cell lines presenting multiple resistance mechanisms might be good models to understand the importance of the various pathways involved. The present work characterized a MDR chronic myeloid leukemia cell line, derived from K562 through a selective process using daunorubicin. This MDR cell line was shown to be resistant to vincristine, daunorubicin, and partially resistant to imatinib. It showed a slower duplication rate. Overexpression of ABCB1 and ABCC1 was observed at the protein and functional levels and the expression of CD95, a molecule related to cell death, was reduced in the MDR cell line. Conversely, no differences were observed related to the anti-apoptotic molecule Bcl-2 or p53 expression. The activation antigen CD69 was reduced in the MDR cell line and treatment with imatinib further decreased the expressed levels. Furthermore, secretion of IL-8 was diminished in the MDR cell line. When daunorubicin-selected cells were compared to another MDR cell line, Lucena 1, derived from the same parental line K562, and selected with vincristine, a different profile was observed in relation to most aspects studied. When both cell lines were silenced for ABCB1, differences in CD69 and CD95 were maintained, despite resistance reversal. These results reinforce the idea that cell lines selected in vitro may display multiple resistance strategies that may vary with the selective agent used as well as during different steps of the selection process.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23877223     DOI: 10.1007/s11010-013-1761-0

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  49 in total

Review 1.  The molecular biology of chronic myeloid leukemia.

Authors:  M W Deininger; J M Goldman; J V Melo
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

2.  Identification of xanthones as selective killers of cancer cells overexpressing the ABC transporter MRP1.

Authors:  Estelle Genoux-Bastide; Doriane Lorendeau; Edwige Nicolle; Samir Yahiaoui; Sandrine Magnard; Attilio Di Pietro; Hélène Baubichon-Cortay; Ahcène Boumendjel
Journal:  ChemMedChem       Date:  2011-06-01       Impact factor: 3.466

Review 3.  The development of imatinib as a therapeutic agent for chronic myeloid leukemia.

Authors:  Michael Deininger; Elisabeth Buchdunger; Brian J Druker
Journal:  Blood       Date:  2004-12-23       Impact factor: 22.113

Review 4.  The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy.

Authors:  Matthew D Hall; Mitsunori Okabe; Ding-Wu Shen; Xing-Jie Liang; Michael M Gottesman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

5.  Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

Authors:  F X Mahon; M W Deininger; B Schultheis; J Chabrol; J Reiffers; J M Goldman; J V Melo
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

Review 6.  CD69 and regulation of the immune function.

Authors:  R Marzio; J Mauël; S Betz-Corradin
Journal:  Immunopharmacol Immunotoxicol       Date:  1999-08       Impact factor: 2.730

7.  Iodination of verapamil for a stronger induction of death, through GSH efflux, of cancer cells overexpressing MRP1.

Authors:  Régis Barattin; Thomas Perrotton; Doriane Trompier; Doriane Lorendeau; Attilio Di Pietro; Amaury du Moulinet d'Hardemare; Hélène Baubichon-Cortay
Journal:  Bioorg Med Chem       Date:  2010-07-17       Impact factor: 3.641

8.  Impairment of Fas-antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumor cells.

Authors:  Z Cai; R Stancou; M Körner; S Chouaib
Journal:  Int J Cancer       Date:  1996-11-15       Impact factor: 7.396

9.  Interaction of imatinib mesilate with human P-glycoprotein.

Authors:  Akinobu Hamada; Hideto Miyano; Hiroshi Watanabe; Hideyuki Saito
Journal:  J Pharmacol Exp Ther       Date:  2003-09-15       Impact factor: 4.030

10.  Sequential emergence of MRP- and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines.

Authors:  D C Zhou; S Ramond; F Viguie; A M Faussat; R Zittoun; J P Marie
Journal:  Int J Cancer       Date:  1996-01-26       Impact factor: 7.396

View more
  15 in total

1.  Silencing the OCT4-PG1 pseudogene reduces OCT-4 protein levels and changes characteristics of the multidrug resistance phenotype in chronic myeloid leukemia.

Authors:  Aline Portantiolo Lettnin; Eduardo Felipe Wagner; Michele Carrett-Dias; Karina Dos Santos Machado; Adriano Werhli; Andrés Delgado Cañedo; Gilma Santos Trindade; Ana Paula de Souza Votto
Journal:  Mol Biol Rep       Date:  2019-02-05       Impact factor: 2.316

2.  The use of natural products to target cancer stem cells.

Authors:  Wesley F Taylor; Ehsan Jabbarzadeh
Journal:  Am J Cancer Res       Date:  2017-07-01       Impact factor: 6.166

3.  Inhibition of glycosphingolipid biosynthesis reverts multidrug resistance by differentially modulating ABC transporters in chronic myeloid leukemias.

Authors:  Eduardo J Salustiano; Kelli M da Costa; Leonardo Freire-de-Lima; Lucia Mendonça-Previato; José O Previato
Journal:  J Biol Chem       Date:  2020-03-30       Impact factor: 5.157

4.  LMWPTP modulates the antioxidant response and autophagy process in human chronic myeloid leukemia cells.

Authors:  Alessandra V S Faria; Stefano P Clerici; Patricia F de Souza Oliveira; Karla C S Queiroz; Maikel P Peppelenbosch; Carmen V Ferreira-Halder
Journal:  Mol Cell Biochem       Date:  2020-02-04       Impact factor: 3.842

5.  Piperlongumine reverses doxorubicin resistance through the PI3K/Akt signaling pathway in K562/A02 human leukemia cells.

Authors:  Qingwei Kang; Shu Yan
Journal:  Exp Ther Med       Date:  2015-02-03       Impact factor: 2.447

Review 6.  Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines?

Authors:  Vivian M Rumjanek; Raphael S Vidal; Raquel C Maia
Journal:  Biosci Rep       Date:  2013-11-25       Impact factor: 3.840

7.  The down-regulation of SLC7A11 enhances ROS induced P-gp over-expression and drug resistance in MCF-7 breast cancer cells.

Authors:  Chun Ge; Bei Cao; Dong Feng; Fang Zhou; Jingwei Zhang; Na Yang; Siqi Feng; Guangji Wang; Jiye Aa
Journal:  Sci Rep       Date:  2017-06-19       Impact factor: 4.379

8.  Metabolic Reprogramming During Multidrug Resistance in Leukemias.

Authors:  Raphael Silveira Vidal; Julia Quarti; Mariana Figueiredo Rodrigues; Franklin D Rumjanek; Vivian M Rumjanek
Journal:  Front Oncol       Date:  2018-04-04       Impact factor: 6.244

9.  Functional Characterization of ABCC Proteins from Trypanosoma cruzi and Their Involvement with Thiol Transport.

Authors:  Kelli Monteiro da Costa; Raphael C Valente; Eduardo J Salustiano; Luciana B Gentile; Leonardo Freire-de-Lima; Lucia Mendonça-Previato; José O Previato
Journal:  Front Microbiol       Date:  2018-02-14       Impact factor: 5.640

Review 10.  Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia.

Authors:  Raquel C Maia; Flavia C Vasconcelos; Paloma S Souza; Vivian M Rumjanek
Journal:  Molecules       Date:  2018-01-07       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.